Evaluation of a 3D Functional Metabolic Imaging and Risk Assessment System in Classifying Women for Likelihood of Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

1200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-23

Study Completion Date

2021-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study objective is to evaluate the added value of MIRA technology as an adjunct to mammography in the detection of malignant breast lesions in women with dense breast and/or at elevated risk of breast cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of a Three Dimensional Functional Metabolic Imaging and Risk Assessment System in Classifying Women for Likelihood of Breast Cancer

NCT03080155

Breast Cancer

UNKNOWN NA

Evaluation of a 3D Functional Metabolic Imaging and Risk Assessment System for Classifying Women at High Risk of Breast Cancer

NCT02777164

Breast Cancer

TERMINATED NA

Evaluation of a Novel Infra-red Breast Imaging System for Risk Assessment in Women at High Risk for Breast Cancer.

NCT02009150

Breast Cancer

UNKNOWN

Evaluation of Real Imaging's 3D Functional Metabolic Imaging and Risk Assessment (MIRA) System

NCT02155075

Breast Cancer

UNKNOWN NA

A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts

NCT03288792

Breast Cancer

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MIRA device imaging

MIRA Device imaging for adjunctive detection of breast cancer

Group Type EXPERIMENTAL

MIRA device imaging

Intervention Type DEVICE

MIRA Device imaging for adjunctive detection of breast cancer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MIRA device imaging

MIRA Device imaging for adjunctive detection of breast cancer

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Real Imager 8

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\*\*Calibration Phase:

A.Subjects who are asymptomatic and scheduled to undergo routine screening mammography.

OR

B.Subjects scheduled for image guided needle biopsy as a result of findings obtained during standard of care (mammography, ultrasound and/or MRI)

\*\*Testing Phase:

A. Subjects scheduled to undergo routine screening mammography and at least one of the following :

* Subjects whose most recent (within 3 years) prior mammogram was interpreted as heterogeneously dense (ACR BI-RADS Breast Density 3) or extremely dense (ACR BI-RADS Breast Density 4).
* Subjects whose current 10-year IBIS breast cancer risk is 5% or higher.

Exclusion Criteria

1. Male by birth.
2. Individual is less than 24 years old.
3. Contraindication to bilateral mammography or MRI.
4. Subjects who are unable to read, understand and execute the informed consent procedure.
5. Subjects who have had mammography, ultrasound or MRI examination performed on the day of the study prior to MIRA scan.
6. Subjects who have significant existing breast trauma.
7. Subjects who have undergone lumpectomy/mastectomy.
8. Subjects who have undergone breast reduction or breast augmentation.
9. Subjects who have undergone any other type of breast surgery.
10. Subjects who have large breast scar / Breast deformation.
11. Subjects who have undergone a breast needle biopsy within the 6 month period prior to their intended enrollment into the study.
12. Subjects who have a temperature \> 100° F (37.8C) degrees on the day of the MIRA imaging.
13. Subjects who are pregnant or lactating.
14. Subjects who have had placement of an internal breast marker.
15. Subjects with known Raynaud's Disease.
16. Subjects that are claustrophobic or have physical limitations that do allow them to sit in the system chair for the required imaging session.
17. Subjects with implanted pacemaker/defibrillator, implanted venous access device (portacath) or other implanted devices.
18. Subjects with a BI-RADS category 6 (e.g. for which mammogram was performed for the purpose of planning cancer therapy).
19. Subjects affected with epilepsy.
20. Subjects who participated in the Calibration Phase will not be able to participate in the Testing Phase.

Minimum Eligible Age

24 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes